Summary
1 - METHOD OF ACTION
Anakinra (KINERET®) is a human interleukin 1 receptor antagonist (r-netHuIL-1ra) produced by recombinant DNA technology using Escherichia coli cells.
It is an immunosuppressant that neutralises the biological activity of interleukin 1α (IL1α) and interleukin 1β (IL1β) by competitively inhibiting binding of IL1 to interleukin 1 type I receptor (IL1 RI).
Interleukin 1 (IL1) is a major pro-inflammatory cytokine mediating many cellular responses including those playing an important role in synovial inflammation.
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!
Therapeutics in Dermatology, Fondation René Touraine © 2001-2014
